Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.20    
    

 
 

CONFIDENTIAL TREATMENT REQUESTED: CONFIDENTIAL PORTIONS OF THIS DOCUMENT
  HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION.    
    

LICENSE AGREEMENT  

        This Agreement is made effective as of the 15th day of may, 1995, by and between Wisconsin Alumni Research Foundation (hereinafter called "WARF"), a nonstock,
nonprofit Wisconsin corporation and Nomos Corporation (hereinafter called "Nomos"), a corporation organized and existing under the laws of Delaware; 

        WHEREAS,
WARF owns certain inventions that are described in the "Licensed Patents" defined below, and WARF is willing to grant a license to Nomos under any one or all of the Licensed
Patents and Nomos desires a license under all of them; 

        NOW,
THEREFORE, in consideration of the mutual covenants and agreements set forth below, the parties covenant and agree as follows: 

Section 1.    Definitions.    

        For
the purpose of this Agreement, the Appendix A definitions shall apply. 

Section 2.    Grant.    

A. LICENSE.  

	(i)
	MEDICAL
IMAGING FIELD LICENSE. 

        WARF
hereby grants to Nomos: (1) a nonexclusive license, limited to the Medical Imaging Field and the Licensed Territory, under the Licensed Patents to make, use, offer to sell
and sell Products; and (2) the right to grant nonexclusive sublicenses under such license to purchasers, lessees and/or users of Products of Nomos to use such Products purchased or leased from
Nomos. 

	(ii)
	ADD-ON
DEVICE FIELD LICENSE. 

        WARF
hereby grants to Nomos: (1) an exclusive license, limited to the Add-on Device Field and the Licensed Territory, under the Licensed Patents to make, use, offer to
sell and sell Products; and (2) the right to grant nonexclusive sublicenses under such license to purchasers, lessees and/or users of Products of Nomos to use such Products purchased or leased
from Nomos. The license granted under Section 2A(ii)(1) shall automatically convert to a nonexclusive license three years after the date of this Agreement. 

	***
	Confidential
material redacted and filed separately with the Commission. 

 
B. LICENSE TO WARF.  

        Licensee hereby grants WARF a nonexclusive, royalty-free, irrevocable, paid-up, worldwide license under the Nomos Patents to make, use and
sell any product that employs or is in any way produced by the practice of an invention claimed in the Nomos Patents or that would otherwise constitute infringement of any claims of the Nomos Patents.
WARF shall have the right to grant sublicenses to others with respect to such rights provided that WARF also has granted such sublicensee a license under the Licensed Patents. 

Section 3.    Consideration.    

A. LICENSE FEE.  

        Nomos agrees to pay to WARF a license fee of $[* * *], with the first $                  due by
June 15, 1995 and the remaining
$[* * *] due by August 31, 1995. 

B. COMPENSATION FOR PRIOR USAGE.  

        Prior to the date of this Agreement, Nomos represents and warrants that it sold a total of nine (9) Products in the Add-On-Device
Field which would require a royalty payment of $[* * *] in accordance with Section 3C if sold pursuant to the terms of this Agreement. In consideration for this prior
usage, Nomos shall pay WARF this additional $[* * *] royalty amount, with the first $[* * *] due by June 15, 1995 and the remaining
$[* * *] due by August 31, 1995. Subject to the receipt of such payment, WARF hereby releases Nomos and its distributors and customers against any claims that WARF may
have for use of the Licensed Patents with respect to the nine (9) Products in the Add-On-Device Field sold prior to the date of this Agreement. [* *
*] 

C. ROYALTY.  

        (i)    In
addition to the payments required by Sections 3A and 3B, Nomos agrees to pay to WARF as "earned royalties" a royalty equal to $[* * *] for
each Product Unit sold or leased by Nomos in the Add-On Device Field after the date of this Agreement. Such royalty rate shall be reduced by [* * *] for any Product
Units sold or leased by Nomos after the date WARF grants a license to any other party under the Licensed Patents in the Add-On Device Field and the Licensed Territory (which shall not
occur before three years after the date of this Agreement). In addition, Nomos shall pay WARF an additional royalty of $[* * *] for each Verification Product Unit leased or
sold in the Add-On-Device Field. [* * *] Nomos agrees to keep the royalty rates, license fee, compensation for prior usage and other commercial terms of
this Agreement confidential using reasonable procedures at least as stringent as those Nomos uses to keep its own sensitive information confidential. 

        (ii)   In
addition to the payments required by Sections 3A and 3B, Nomos agrees to pay to WARF as "earned royalties" a royalty equal to $[* * *] for
each Product Unit sold or leased by Nomos outside of the Add-On-Device Field after the date of this Agreement. 

        (iii)  A
Product Unit is deemed sold or leased and a royalty is deemed earned under this Agreement as of the earlier of the date the Product Unit is actually sold and paid
for, the date an invoice is sent by Nomos, the date a lessee takes possession of a Product Unit, or the date a Product Unit is otherwise transferred to a third party for consideration (excluding
transfers of Product Units to third parties solely for research purposes if Nomos does not receive any monetary consideration with respect to such transfer). If Nomos sells a Product Unit that is
later returned by the customer with Nomos repaying the customer the full consideration paid therefor (excluding a restocking fee which may be retained by Nomos of up to $[* *
*] per Product Unit returned), then no royalty shall be charged with respect to such Product Unit and, to the extent any royalty was previously paid to WARF 

2

 

with
respect to such Product Unit, the royalty shall be credited against future royalties payable to WARF under this Agreement. 

        (iv)  WARF
is exempt from paying income taxes under U.S. law. Therefore, all payments due under this Agreement shall be made without deduction for taxes, assessments, or
other charges of any kind which may be imposed on WARF by any government outside of the United States or any political subdivision of such government with respect to any amounts payable to WARF
pursuant to this Agreement. All such taxes, assessments, or other charges shall be assumed by Nomos. 

D. MINIMUM ROYALTY.  

        Nomos further agrees to pay to WARF a minimum royalty of $[* * *] per calendar year or part thereof during which this Agreement is in
effect starting in calendar year 1996, against which any earned royalty paid for the same calendar year will be credited. The minimum royalty for a given year shall be due at the time payments are due
for the calendar quarter ending on December 31. It is understood that the minimum royalties will apply on a calendar year basis, and that sales of Products requiring the payment of earned
royalties made during a prior or subsequent calendar year shall have no effect on the annual minimum royalty due WARF for any given calendar year. 

 
 

E. ACCOUNTING; PAYMENTS.    
    

        (i)    Amounts
owing to WARF under Section 3C shall be paid on a quarterly basis, with such amounts due and received by WARF on or before the thirtieth day following the
end of the calendar quarter ending on March 31, June 30, September 30 or December 31 in which such amounts were earned. The balance of any amounts which remain unpaid more
than thirty (30) days after they are due to WARF shall accrue interest until paid at the rate of the lesser of one percent (1%) per month or the maximum amount allowed under applicable law.
However, in no event shall this interest provision be construed as a grant of permission for any payment delays. 

        (ii)   Except
as otherwise directed, all amounts owing to WARF under this Agreement shall be paid in U.S. dollars to WARF at the address provided in Section 16(a). All
royalties owing with respect to Selling Prices stated in currencies other than U.S. dollars shall be converted at the rate shown in the Federal Reserve Noon Valuation—Value of Foreign
Currencies on the day preceding the payment. 

        (iii)  A
full accounting showing how any amounts owing to WARF under Section 3C have been calculated shall be submitted to WARF on the date of each such payment. Such
accounting shall be on a per-country and model or tradename basis and shall be summarized on the form shown in Appendix C of this Agreement. Such accounting shall also describe any
returned Product Units for which Nomos is requesting a credit and the amount of the restocking fee retained by Nomos with respect to such Product Unit. In the event no payment is owed to WARF, a
statement setting forth that fact shall be supplied to WARF. 

Section 4.    Warranties.    

A. CERTAIN WARRANTIES OF WARF.  

        (i)    WARF
warrants that except as otherwise provided under Section 14 of this Agreement with respect to U.S. Government interests, it is the owner of the Licensed
Patents and has the right to enter into this Agreement. However, nothing in this Agreement shall be construed as: 

        (1)   a
warranty or representation by WARF as to the validity or scope of any of Licensed Patents; 

        (2)   a
warranty or representation that anything made, used, sold or otherwise disposed of under the license granted in this Agreement will or will not infringe patents of
third parties; 

3

 

        (3)   except
as otherwise expressly provided in Section 10, an obligation to bring or prosecute actions or suits against third parties for infringement of Licensed
Patents; 

        (4)   an
obligation to furnish any know-how not provided in Licensed Patents; or 

        (5)   a
warranty or representation by WARF that it will not grant licenses to others to make, use or sell products not covered by the claims of the Licensed Patents which may
be similar and/or compete with Products made or sold by Nomos. 

        (ii)   WARF
MAKES NO REPRESENTATIONS, EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND ASSUMES NO RESPONSIBILITIES WHATSOEVER WITH RESPECT TO USE, SALE, OR
OTHER DISPOSITION BY NOMOS OR ITS VENDEES OR OTHER TRANSFEREES OF PRODUCTS INCORPORATING OR MADE BY USE OF INVENTIONS LICENSED UNDER THIS AGREEMENT. 

B. CERTAIN WARRANTIES AND RESPONSIBILITIES OF NOMOS.  

        Nomos warrants that it has, or will obtain, the expertise necessary to independently evaluate the inventions of the Licensed Patents. All development activities
and strategies and all aspects of Products design and decisions to market and the like are entirely at the discretion of Nomos, and Nomos shall rely entirely on its own expertise with respect thereto. 

Section 5.    RECORDKEEPING.    

        A.    Nomos
shall keep books and records sufficient to verify the accuracy and completeness of Nomos's accounting referred to above. Such books and records shall be preserved
for a period not less than six years after they are created during and after the term of this Agreement. 

        B.    Nomos
shall take all steps necessary so that WARF may within thirty days of its request review and copy all the books and records at a single U.S. location to verify the
accuracy of Nomos's accounting. Such review may be performed by any licensing or accounting employee of WARF as well as by any attorney or registered CPA designated by WARF, upon reasonable notice and
during regular business hours. 

        C.    If
a royalty payment deficiency is determined, Nomos shall pay the royalty deficiency outstanding within thirty (30) days of receiving written notice thereof, plus
interest on outstanding amounts as described in Section 3E(i). 

        D.    If
a royalty payment deficiency for a calendar year exceeds five percent (51) of the royalties paid for that year, then Nomos shall be responsible for paying
WARF's out-of-pocket expenses incurred with respect to such review. 

Section 6.    TERM; TERMINATION.    

        A.    The
term of this license shall begin on the effective date of this Agreement and continue until the earlier of the date that no Licensed Patent remains an enforceable
patent or the payment of earned royalties under Section 3C, once begun, ceases for more than four (4) calendar quarters. 

        B.    Nomos
may terminate this Agreement at any time by giving at least ninety days' written and unambiguous notice of such termination to WARF. Such a notice shall be
accompanied by a statement of the reasons for termination. 

        C.    If
Nomos at any time defaults in the timely payment of any monies due to WARF or commits any breach of any other covenant herein contained, and Nomos fails to remedy any
such breach or default within ninety days after written notice thereof by WARF, WARF may, at its option, terminate this Agreement by giving notice of termination to Nomos. 

4

 

        D.    Upon
the termination of this Agreement, Nomos shall remain obligated to provide an accounting for and to pay royalties earned up to the date of the termination and any
minimum royalties shall be prorated as of the date of termination by the number of days elapsed in the applicable calendar year. The provisions of Sections 2B and 8 of this Agreement, and Sections
2A(i)(2) and 2A(ii)(2) to the extent all applicable royalties have been paid by Nomos with respect to the Products used pursuant to such sections, shall survive the termination of this Agreement. 

Section 7    ASSIGNABILITY.    

        This
Agreement may not be transferred or assigned by Nomos except with the prior written consent of WARF, which consent shall not be unreasonably withheld. If WARF consents to a transfer
or assignment, the royalty rate for Products leased or sold in the Add-On-Device Field shall be increased to $[* * *] per Product Unit (plus
$[* * *] for Verification Product Units) and the [* * *] royalty reduction specified in Section 3C shall thereafter be void. 

Section 8.    ASSIGNMENT OF CERTAIN CLAIMS.    

        In
consideration for the license grants make herein, Nomos hereby agrees to assign and transfer to WARF complete title and right to any patent claims which would, if allowed, result in
the declaration of an interference with any claim issued or pending now, or any claim pending or issued in the future, contained in any Licensed Patent. Should Nomos become aware of any potentially
interfering claim or claims, or any right to prosecute an interfering claim or claims, then Nomos shall inform WARF of such claims or rights to claims, after which such claim or claims shall, under
the provisions of this paragraph, become the property of WARF. Nomos shall also freely supply to WARF any and all information and copies of records reasonably requested by WARF or its counsel, which
information or records are necessary and relevant to a determination of the dates of invention by any named inventors in any Nomos patent application. Nomos and WARF shall confer regarding such
information or records and their respective opinions as to dates of invention by the respective inventors. If WARF should determine, after due investigation and due consideration of Nomos's
information and opinions, that one or more Nomos inventors can establish earlier dates of invention than previously named inventors who have assigned to WARF, then WARF shall take such action as
appropriate to prosecute
its patent rights and/or to correct its patents so as to name such a Nomos inventor as an inventor on a WARF patent or patent application. Nomos agrees to execute, and to require any inventors named
on its patent applications to execute, any declarations of fact or documents of title necessary to accomplish the objectives of this paragraph. 

Section 9.    CONTEST OF VALIDITY.    

        In
the event Nomos contests the validity of any Licensed Patent, Nomos shall continue to pay royalties with respect to that patent as if such contest were not underway until the patent
is adjudicated invalid or unenforceable by a court of last resort. 

Section 10.    ENFORCEMENT.    

        A.    WARF
intends to protect Licensed Patents against infringers or otherwise act to eliminate infringement, when, in WARF's sole judgment, such action may be reasonably
necessary, proper, and justified, and any enforcement proceedings shall be under WARF's sole control. In the event that Nomos believes there is infringement of any Licensed Patent under this Agreement
which is to Nomos's substantial detriment, Nomos shall provide WARF with notification and reasonable evidence of such infringement. 

        B.    If,
during the period that the license granted in Section 2A(ii) remains exclusive, the infringement of a Licensed Patent in the United States is to Nomos's
substantial detriment for a 

5

 

Product
licensed to Nomos in the Add-On-Device Field hereunder and such infringement has continued for six months after Nomos has provided WARF with: 

          (i)  a
written request that WARF take action to abate or terminate such infringement, 

         (ii)  reasonable
evidence of the infringement, and 

        (iii)  a
clear opinion, by an outside patent counsel acceptable to WARF, that is addressed to WARF and that unconditionally states that the complained of activity is an
infringement and that enforcement of the Licensed Patent will not constitute patent misuse or abuse, 

        then
WARF shall notify Nomos that WARF will, at its sole option, either: 

          (i)  bring
an infringement action in WARF's own name, in which case WARF shall be responsible for all expenses incurred with respect thereto (including attorneys fees) and
WARF shall be entitled to any damages recovered therein; 

         (ii)  bring
an infringement action jointly with Nomos, in which case Nomos and WARF shall be each be responsible for paying fifty percent (50%) of the expenses incurred with
respect thereto (including attorneys fees), Nomos and WARF shall each be entitled to a share of fifty percent (50%) of the aggregate damages recovered therein, and WARF shall control the prosecution
of such action (provided Nomos shall have the right to consult with WARF regarding major decisions arising in the action and WARF shall give due consideration to Nomos's opinions with respect
thereto); or 

        (iii)  permit
Nomos to bring an infringement action, in which case Nomos shall have right to file a lawsuit to seek to stop such activity at its own expense and be
entitled to any damages covered therein (with royalties payable to WARF under Section 3C based on the number of Product Units sold or leased by the infringer for which Nomos obtained damages);
provided that during such litigation Nomos shall act in good faith to preserve WARF's right, title and interest in and to the Licensed Patent, shall keep WARF advised as to the status of the
litigation and shall not enter into a settlement of such litigation without first allowing WARF the option of either approving the settlement or of continuing the litigation at WARF's expense for
WARF's benefit (upon payment to Nomos of its out-of-pocket costs and expenses, including attorneys fees, incurred in the litigation). 

        If
WARF has elected to bring an infringement action in WARF's own name pursuant to clause (i) above, Nomos may elect to require such that action be brought jointly with Nomos as
provided in clause (ii) by notifying WARF of Nomos's election in writing within thirty (30) days after receiving notice from WARF of WARF's election. Nothing herein shall permit or allow
Nomos to commence any action for infringement of the Licensed Patent for any activity allowed under a settlement arrangement entered into by WARF in good faith with a third party infringer. 

Section 11.    PATENT MARKING.    

        Nomos
shall insure that it applies patent markings that meet all requirements of U.S. law, 35 U.S.C. 287, with respect to all Products subject to this Agreement. An example of an
acceptable label is "Covered by one or more of the following patents: [list all applicable patent numbers]." 

Section 12.    PRODUCT LIABILITY; CONDUCT OF BUSINESS.    

        A.    Nomos
shall, at all times during the term of this Agreement and thereafter, indemnify, defend and hold WARF and the inventors of the Licensed Patents harmless against all
claims and expenses, including legal expenses and reasonable attorneys fees, arising out of the death of or injury to any person or persons or out of any damage to property and against any other
claim, proceeding, demand, expense and liability of any kind whatsoever (other than patent infringement claims) resulting from the production, manufacture, sale, use, lease, consumption or
advertisement of Products arising from any 

6

 

right
or obligation of Nomos hereunder. Notwithstanding the above, WARF at all times reserves the right to retain counsel of its own, at WARF's expense, to defend WARF's interests. 

        B.    Nomos
warrants that it now maintains and will continue to maintain liability insurance coverage appropriate to the risk involved in marketing the products subject to this
Agreement and that such insurance coverage lists WARF and the inventors of the Licensed Patents as additional insureds. Within ninety (90) days after the execution of this Agreement and
thereafter annually between January 1 and January 31 of each year, Nomos will present evidence to WARF that the coverage is being maintained with WARF and its inventors listed as
additional insureds. In addition, Nomos shall provide WARF with at least 30 days prior written notice of any change in or cancellation of the insurance coverage. 

        C.    If
WARF grants any third party a sublicense under the Nomos Patents, and WARF's agreement with such third party requires the third party to indemnify, defend, or obtain
insurance protecting WARF from claims relating to the patents licensed under such agreement, then such agreement shall also require the third party to indemnify, defend and obtain insurance protecting
Nomos and Mark Carol to the same extent that such party has agreed to indemnify, defend and obtain insurance protecting WARF. However, WARF shall not be responsible for the actions or obligations of
any such third party, WARF shall not be obligated to monitor or enforce such obligations in the agreement, and WARF shall have no obligation to indemnify, defend or obtain insurance protecting Nomos
or Mark Carol or any other party from any actions or claims whatsoever. 

        D.    If
WARF grants any third party a license under any WARF-owned patents in which Mark Carol is a named inventor, and WARF's agreement with such third party
requires the third party to indemnify, defend, or obtain insurance protecting WARF's inventors from claims relating to the patents licensed under such agreement, then such agreement shall also require
the third party to indemnify, defend and obtain insurance protecting Mark Carol to the same extent that such party has agreed to indemnify, defend and obtain insurance protecting WARF's inventors.
However, WARF shall not be responsible for the actions or obligations of any such third party, WARF shall not be obligated to monitor or enforce such obligations in the agreement, and WARF shall have
no obligation to indemnify, defend or obtain insurance protecting Mark Carol or any other party from any actions or claims whatsoever. 

Section 13.    USE OF NAMES.    

        Except
as required under Section 11, Nomos shall not use WARF's name, the name of any inventor of inventions governed by this Agreement, or the name of the University of Wisconsin
in sales promotion, advertising, or any other form of publicity without the prior written approval of the entity or person whose name is being used. 

Section 14.    UNITED STATES GOVERNMENT INTERESTS.    

        It
is understood that if the United States Government (through any of its agencies or otherwise) has funded research, during the course of or under which any of the inventions of the
Licensed Patents were conceived or made, the United States Government is entitled, as a right, under the provisions of 35 U.S.C. ss. 200-212 and applicable regulations of Chapter 37 of the
Code of Federal Regulations, to a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced the invention of such Licensed Patents for governmental
purposes. Any license granted to Nomos in this Agreement shall be subject to such right. 

Section 15.    MISCELLANEOUS.    

        This
Agreement shall be construed in accordance with the internal laws of the State of Wisconsin. If any provisions of this Agreement are or shall come into conflict with the laws or
regulations of any jurisdiction or any governmental entity having jurisdiction over the parties or this Agreement, those 

7

 

provisions
shall be deemed automatically deleted, if such deletion is allowed by relevant law, and the remaining terms and conditions of this Agreement shall remain in full force and effect. If such a
deletion is not so allowed or if such a deletion leaves terms thereby made clearly illogical or inappropriate in effect, the parties agree to substitute new terms as similar in effect to the present
terms of this Agreement as may be allowed under the applicable laws and regulations. The parties hereto are independent contractors and not joint venturers or partners. 

Section 16.    NOTICES.    

        Any
notice required to be given pursuant to the provisions of this Agreement shall be in writing and shall be deemed to have been given at the earlier of the time when actually received
as a consequence of any effective method of delivery, including but not limited to hand delivery, transmission by facsimile, or delivery by a professional courier service or the time when sent by
certified or registered
mail addressed to the party for whom intended at the address below or at such changed address as the party shall have specified by written notice, provided that any notice of change of address shall
be effective only upon actual receipt. 

        (a)   Wisconsin
Alumni Research Foundation Attn: Managing Director 614 Walnut Street Madison, Wisconsin 53705 

        (b)   Nomos
Corporation Attn: President 2591 Wexford Bayne Road Suite 400 Sewickley, PA 15143 

Section 17    INTEGRATION.    

        This
Agreement constitutes the full understanding between the parties with reference to the subject matter hereof, and no statements or agreements by or between the parties, whether
orally or in writing, except as provided for elsewhere in this Section 17, made prior to or at the signing hereof, shall vary or modify the written terms of this Agreement. Neither party shall
claim any amendment, modification, or release from any provisions of this Agreement by mutual agreement, acknowledgement, or otherwise, unless such mutual agreement is in writing, signed by the other
party, and specifically states that it is an amendment to this Agreement. 

Section 18    AUTHORITY.    

        The
persons signing on behalf of WARF and Nomos hereby warrant and represent that they have authority to execute this Agreement on behalf of the party for whom they have signed. 

8

 

        IN
WITNESS WHEREOF, the parties hereto have duly executed this Agreement on the dates indicated below. 

	WISCONSIN ALUMNI RESEARCH FOUNDATION	 	 
	

By:	
 	

/s/  RICHARD H. LEAZER      
 Richard H. Leazer, Managing Director	
 	

Date:    June 19, 1995
	
NOMOS CORPORATION	
 	

 
	

By:	
 	

/s/  MARK CAROL      
 Mark Carol, M.D. President	
 	

Date:    6/5, 1995
	

Reviewed by WARF's Attorney:	
 	

Reviewed by Nomos's Attorney:
	

/s/  [ILLEGIBLE]      
	
 	

/s/  BEN D. TOBOR      

	

June 1, 1995	
 	

6/9,95

(Neither
attorney shall be deemed a signatory to this Agreement.) 

9

 
 
  APPENDIX A    
    

        A.    "Licensed
Patents" shall refer to and mean those patents and patent applications listed on Appendix B hereto that are in countries in the Licensed Territory and
any subsequent patent application owned by WARF in a country in the Licensed Territory but only to the extent it claims an invention claimed in a patent application listed on Appendix B in such
country. 

        B.    "Verification
Patents" shall refer to and mean U.S. Patent No. 5,394,452 and any foreign Licensed Patent, but only to the extent such foreign Licensed Patent
claims an invention equivalent to the invention claimed in U.S. Patent No. 5,394,452. 

        C.    "Nomos
Patents" shall refer to and mean U.S. Patent Application Serial No. 08/284,279, currently entitled "Method and Apparatus for Conformal Radiation Therapy,"
any foreign equivalents thereof, and any subsequent patent application owned by Nomos but only to the extent: (i) it claims an invention claimed in such U.S. or foreign patent applications;
(ii) it is not limited to a non-slice-by-slice radiation therapy apparatus; and (iii) it is not limited to a non-fan beam radiation
therapy apparatus. 

        D.    "Product"
shall mean any radiation therapy apparatus that employs or is in any way produced by the practice of an invention claimed in the Licensed Patents (whether
issued or pending) or that would otherwise constitute infringement of any claims of the Licensed Patents (whether issued or pending). The parties agree that "Product" shall include any treatment
planning system software as long as claim 7 of U.S. Patent Application No. 08/191,243 remains pending (in the original application or any derivative thereof) or has been issued. If claim 7 is
abandoned and the treatment planning system software does not at any time employ and is not in any way produced by the practice of any other claim of any Licensed Patent (whether issued or pending)
and would not otherwise constitute infringement of any Licensed Patent (whether issued or pending), then such software shall not thereafter constitute a Product hereunder. 

        E.    "Verification
Product" shall mean any Product that employs or is in any way produced by the practice of an invention claimed in the Verification Patents (whether issued
or pending), except claim #6 of the U.S. Verification Patent and the equivalent claim(s) in any foreign application, or any Product that would otherwise constitute infringement of any claims of the
Verification Patents (whether issued or pending), except claim #6 of the U.S. Verification Patent and the equivalent claim(s) in any foreign application. 

        F.     "Unit"
shall mean any single radiation therapy apparatus or item of software, regardless of whether such apparatus or item of software is packaged with other radiation
therapy apparatuses, software or any other products. 

        G.    "Medical
Imaging Field" shall be limited to the field of medical imaging devices. 

        H.    "Add-On
Device Field" shall be limited to the field of the manufacture of Products solely as an Add-On Accessory to a Constrained Rotation Linear
Accelerator made by a third party who is neither the Add-On Accessory manufacturer nor an Affiliate of the Add-On Accessory manufacturer, where the combined device is intended
for use only in the Medical Imaging Field. 

        I.     "Add-On
Accessory" shall mean any add-on accessory or software (including without limitation the treatment planning system software) designed to
operate in conjunction with a Constrained Rotation Linear Accelerator, except that the term "Add-On Accessory" shall not include either the linear accelerator itself or any Beam Directing
Device. 

        J.     "Beam
Directing Device" shall mean any gantry or other device or method for directing or redirecting the beam from a linear accelerator or otherwise changing the angle of
such a beam. 

10

 

        K.    "Constrained
Rotation Linear Accelerator" shall mean any linear accelerator in combination with a Beam Directing Device in which the output beam cannot be rotated more
than 360 degrees in a single direction of arc. 

        L.    "Affiliate
of the Add-On Accessory Manufacturer" shall mean: 

          (i)  any
person or entity directly or indirectly owning or controlling at least twenty percent (20%) of the equity interest normally entitled to vote for election of the
management of the Add-On Accessory Manufacturer; and 

         (ii)  any
entity in which either the Add-on Accessory Manufacturer or a person or entity described in subparagraph W directly or indirectly owns or controls at
least fifty percent (50%) of the equity interest normally entitled to vote for election of the management of such entity. 

        M.   "Licensed
Territory" shall be worldwide. 

11

 
APPENDIX B  

 LICENSED PATENTS AND PATENT APPLICATIONS  

	Reference Number
 
	 	Country
	 	Patent Number
	 	Issue Date
	 	Serial Number

	METHOD AND APPARATUS FOR RADIATION THERAPY (SWERDLOFF, MACKIE, HOLMES)	 	 
	

P91009US	
 	

U.S.	
 	

5,317,616	
 	

5/31/94	
 	

 
	P91009AU	 	Australia	 	 	 	 	 	35323/93
	P91009CA	 	Canada	 	 	 	 	 	2091275
	P91009EP	 	EPO	 	 	 	 	 	93301672.7
	P91009IL	 	Israel	 	 	 	 	 	104896
	P91009JP	 	Japan	 	 	 	 	 	5-58983
	P91009KR	 	South Korea	 	 	 	 	 	4146/1993
	P91009MX	 	Mexico	 	 	 	 	 	931495
	P91009NZ	 	New Zealand	 	 	 	 	 	247042
	

MULTI-LEAF RADIATION ATTENUATOR FOR RADIATION THERAPY (SWERDLOFF, MACKIE, HOLMES)	
 	

 
	

P92142US	
 	

U.S.	
 	

5,351,280	
 	

9/27/94	
 	

 
	P92142WO	 	PCT	 	 	 	 	 	US94/06487
	RADIATION THERAPY SYSTEM WITH CONSTRAINED ROTATIONAL FREEDOM (SWERDLOFF, MACKIE, HOLMES)	 	 
	P92135US	 	U.S.	 	 	 	 	 	08/071,742
	P92135US	 	PCT	 	 	 	 	 	US94/06488
	

DYNAMIC COLLIMATOR FOR RADIATION THERAPY (SWERDLOFF, MACKIE, HOLMES, RECKWERDT)	
 	

 
	

P92138US	
 	

U.S.	
 	

 	
 	

 	
 	

08/071,741
	

METHOD AND APPARATUS FOR RADIATION THERAPY (SWERDLOFF, MACKIE, HOLMES)	
 	

 
	

P94001	
 	

U.S.	
 	

 	
 	

 	
 	

08/191,243
	

RADIATION THERAPY SYSTEM WITH CONSTRAINED ROTATIONAL FREEDOM (SWERDLOFF, MACKIE, HOLMES)	
 	

 
	

P95061	
 	

U.S.	
 	

 	
 	

 	
 	

[To be filed]
	

VERIFICATION SYSTEM FOR RADIATION THERAPY (SWERDLOFF, MACKIE, HOLMES)	
 	

 
	P92140	 	U.S.	 	5,394,452	 	 	 	2/28/95
	

DYNAMIC BEAM FLATTENING APPARATUS FOR RADIATION THERAPY (SWERDLOFF, MACKIE, HOLMES)	
 	

 
	P92137US	 	U.S.	 	 	 	 	 	08/074,192
	P92137US	 	PCT	 	 	 	 	 	US94/06489

12

QuickLinks

Exhibit 10.20

CONFIDENTIAL TREATMENT REQUESTED: CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION.

E. ACCOUNTING; PAYMENTS.

APPENDIX AQuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.21    
    

 
  PATENT LICENSE AGREEMENT    
    

        THIS Agreement is between the Board of Regents ("Board") of The University of Texas System ("System"), an agency of the State of Texas, whose address is 201 West
7th Street, Austin, Texas 78701, and NOMOS CORPORATION, a Delaware corporation having a principal place of business located at 2591 Wexford Bayne Road, Sewickley, PA 15143 ("Licensee"). Board and
Licensee shall be hereinafter referred to collectively as the "Parties" and individually as the "Party." 

TABLE OF CONTENTS  

	 	 	RECITALS	 	1
	1.	 	EFFECTIVE DATE	 	1
	2.	 	DEFINITIONS	 	1
	3.	 	WARRANTY, SUPERIOR RIGHTS	 	2
	4.	 	LICENSE	 	3
	5.	 	PAYMENTS AND REPORTS	 	3
	6.	 	TERM AND TERMINATION	 	5
	7.	 	INFRINGEMENT BY THIRD PARTIES	 	6
	8.	 	ASSIGNMENT	 	6
	9.	 	PATENT MARKING	 	6
	10.	 	INDEMNIFICATION	 	6
	11.	 	USE OF BOARD AND COMPONENT'S NAME	 	6
	12.	 	CONFIDENTIAL INFORMATION	 	7
	13.	 	PATENTS AND INVENTORS	 	7
	14.	 	ALTERNATE DISPUTE RESOLUTION	 	7
	15.	 	GENERAL	 	8
	 	 	SIGNATURES	 	9

 
 

EXECUTION COPY    
    
    RECITALS    
    

	A.
	Board
owns certain Patent Rights and Technology Rights related to Licensed Subject Matter, which were developed at The University of Texas Health Science Center at San Antonio
("University"), a component institution of System.

	B.
	Board
desires to have the Licensed Subject Matter developed and used for the benefit of Licensee, Inventor, Board, and the public as outlined in Board's Intellectual Property Policy.

	C.
	Licensee
wishes to obtain a license from Board to practice Licensed Subject Matter. 

NOW,
THEREFORE, in consideration of the mutual covenants and premises herein contained, the parties agree as follows: 

	1.
	EFFECTIVE
DATE 

This
Agreement is effective October 21, 1998 ("Effective Date"). 

	2.
	DEFINITIONS 

As
used in this Agreement, the following terms have the meanings indicated: 

	2.1
	"Affiliate"
means any business entity more than 50% owned by Licensee, any business entity which owns more than 50% of Licensee, or any business entity that is more than 50% owned by
a business entity that owns more than 50% of Licensee.

	2.2
	"Licensed
Field" means all radiation therapy applications deriving from the Patent Rights or Technology Rights. 

 
	2.3
	"Licensed
Product" means any product Sold by Licensee comprising Licensed Subject Matter pursuant to this Agreement.

	2.4
	"Licensed
Subject Matter" means inventions and discoveries covered by Patent Rights or Technology Rights within Licensed Field.

	2.5
	"Licensed
Territory" means world-wide.

	2.6
	"Net
Sales" means the gross revenues received by Licensee from the Sale of Licensed Products less sales and/or use taxes actually paid, import and/or export duties actually paid,
outbound transportation prepaid or allowed, and amounts allowed or credited due to returns (not to exceed the original billing or invoice amount).

	2.7
	"Patent
Rights" means Board's rights in information or discoveries covered by United States Patent Application filed on October 21, 1998 entitled "Couch Mounted Tomotherapy
Treatment Device and Methods of Using the Same" by Bill J. Salter ("Inventor") and all divisions, continuations, continuations-in-part, reissues, reexaminations or extensions
thereof, and any letters patent that issue thereon, whether domestic or foreign.

	2.8
	"Peacock(R)
System" means a system for the delivery of intensity modulated radiation therapy comprising the CORVUS Inverse Treatment Planning System (or its functional equivalent)
and/or the MIMiC Multileaf Collimator (or its functional equivalent), as they may be modified from time to time.

	2.9
	"Sale
or Sold" means the transfer or disposition of a Licensed Product for value to a party other than Licensee.

	2.10
	"Technology
Rights" means Board's rights in technical information, know-how, processes, procedures, compositions, devices, methods, formulas, protocols, techniques,
software, designs, drawings or data created by Inventor at University before or after the Effective Date relating to apparatus and methods for delivering radiation therapy which are not covered by
Patent Rights, but which are necessary for practicing the invention covered by Patent Rights.

	3.
	WARRANTY:
SUPERIOR-RIGHTS

	3.1
	Except
for the rights, if any, of the Government of the United States, as set forth below, Board represents and warrants its belief to the best of its knowledge, after due inquiry,
that (i) it is the owner of the entire right, title, and interest in and to Licensed Subject Matter, (ii) it has the sole right to grant licenses thereunder, and (iii) it has not
knowingly granted licenses thereunder to any other entity that would restrict rights granted to Licensee except as stated herein.

	3.2
	Licensee
understands that the Licensed Subject Matter may have been developed under a funding agreement with the Government of the United States of America (the "Government") and, if
so, that the Government may have certain rights relative thereto. This Agreement is explicitly made subject to the Government's rights under any agreement and any applicable law or regulation. If
there is a conflict between an agreement, applicable law or regulation and this Agreement, the terms of the Government agreement, applicable law or regulation shall prevail. The Board shall be
responsible for any payments or fees of any kind payable to the Government of the United States under any such agreement, law or regulation. To the best of Board's knowledge, this Agreement does not
conflict with or require the approval of the Government.

	3.3
	Licensee
understands and acknowledges that Board, by this Agreement, makes no representation as to the operability or fitness for any use, safety, efficacy, ability to obtain
regulatory approval, patentability, and/or breadth of the Licensed Subject Matter. Board, by this Agreement, also makes no representation as to whether there are any patents now held, or which will be
held, by others or by Board in the Licensed Field, nor does Board make any representation that the inventions 

2

 

contained
in Patent Rights do not infringe any other patents now held or that will be held by others or by Board. 

	3.4
	Licensee,
by execution hereof, acknowledges, covenants, and agrees that it has not been induced in any way by Board, System, University or its employees to enter into this Agreement,
and further warrants and represents that: (i) it has conducted sufficient due diligence with respect to all items and issues pertaining to this Article 3 and all other matters pertaining
to this Agreement; and (ii) Licensee has adequate knowledge and expertise, or has utilized knowledgeable and expert consultants, to adequately conduct the due diligence, and agrees to accept
all risks inherent herein.

	4.
	LICENSE

	4.1
	Board
hereby grants to Licensee a royalty-bearing, exclusive license under Licensed Subject Matter to manufacture, have manufactured, import, offer to sell, and/or sell Licensed
Products within the Licensed Territory for use within Licensed Field. This grant is subject to the payment by Licensee to Board of all consideration as provided herein, and is further subject to
rights retained by Board to:

	a.
	Publish
the general scientific findings from research related to Licensed Subject Matter subject to the terms of Article 12, Confidential Information; and

	b.
	Use
Licensed Subject Matter for research, teaching, and other educationally-related purposes.

	4.2
	Licensee
may extend the license granted herein to any Affiliate if the Affiliate consents to be bound by this Agreement to the same extent as Licensee.

	4.3
	Licensee
may grant sublicenses consistent with this Agreement if Licensee is responsible for the operations of its sublicensees relevant to this Agreement as if the operations were
carried out by Licensee, including the payment of royalties whether or not paid to Licensee by a sublicensee. Licensee must deliver to Board a true and correct copy of each sublicense granted by
Licensee, and any modification or termination thereof, within 30 days after execution, modification, or termination. When this Agreement is terminated, all existing sublicenses granted by
Licensee must terminate as well. This termination right does not apply to products previously sold to third parties for use in the Peacock(R) System.

	5.
	PAYMENTS
AND REPORTS

	5.1
	In
consideration of rights granted by Board to Licensee under this Agreement, Licensee will pay Board the following:

	(a.)
	a
non-refundable license documentation fee in the amount of $25,000 due and payable when this Agreement is executed by Licensee;

	(b.)
	a
royalty of $4,000 for the Sale, in conjunction with the Sale of a Peacock(R) System, of a Licensed Product capable of translating a radiation therapy treatment couch solely via
manual operation (i.e., the motive force for translation is supplied via direct physical manipulation of the Licensed Product by an operator thereof) ("Manual Licensed Product");

	(c.)
	a
royalty of $5,000 for the Sale, in conjunction with the Sale of a Peacock(R) System, of a Licensed Product capable of translating a radiation therapy treatment couch by means other
than or in addition to manual operation ("Self-motive Licensed Product");

	(d.)
	a
running royalty equal to 20% of Net Sales or a royalty of $4,000, whichever is greater, for each Manual Licensed Products Sold independently from the Sale of a Peacock(R) System
and covered by Patent Rights or Technology Rights; 

3

 

	(e.)
	a
running royalty equal to 15% of Net Sales or a royalty of $5,000, whichever is greater, for each Self-motive Licensed Product Sold independently from the Sale of a
Peacock(R) System and covered by Patent Rights or Technology Rights; and

	(f.)
	minimum
yearly royalties of $100,000 due within 30 days of the first anniversary, $125,000 due within 30 days of the second anniversary, and $125,000 due within
30 days of the third anniversary of the first Sale of a Licensed Product.

	5.2
	During
the Term of this Agreement and for 1 year thereafter, Licensee agrees to keep complete and accurate records of its and its sublicensees' Sales and Net Sales of Licensed
Products under the license granted in this Agreement in sufficient detail to enable the royalties payable hereunder to be determined. Licensee agrees to permit Board or its representatives, at Board's
expense, to periodically examine its books, ledgers, and records during regular business hours for the purpose of and to the extent necessary to verify any report required under this Agreement, but
not more than twice in any calendar year. If the amounts due to Board are determined to have been underpaid by more than five (5%) percent of the correct amount due, Licensee will pay the cost of the
examination and accrued interest at the rate of twelve (12%) percent per annum.

	5.3
	Within
30 days after March 31, June 30, September 30, and December 31, beginning immediately after the Effective Date, Licensee must deliver to
Board a true and accurate written report, even if no payments are due Board, giving the particulars of the business conducted by Licensee and its sublicensee(s), if any exist, during the preceding 3
calendar months under this Agreement as are pertinent to calculating payments hereunder. This report will include at least:

	a.
	the
quantities of Licensed Subject Matter that it has produced;

	b.
	the
total Sales;

	c.
	the
calculation of royalties thereon; and

	d.
	the
total royalties computed and due Board. 

Simultaneously
with the delivery of each report, Licensee must pay to Board the amount, if any, due for the period of each report. 

	5.4
	On
or before each anniversary of the Effective Date, irrespective of having a first Sale or offer for Sale, Licensee must deliver to Board a written progress report as to Licensee's
(and any sublicensee's) efforts and accomplishments during the preceding year in diligently commercializing Licensed Subject Matter in the Licensed Territory and Licensee's (and, if applicable,
sublicensee's) commercialization plans for the upcoming year.

	5.5
	All
amounts payable here by Licensee must be paid in United States funds without deductions for taxes, assessments, fees, or charges of any kind, except as required by applicable law.
Checks must be payable to Board of Regents, The University of Texas System, and shall be delivered to: 

R.
B. Price

Executive Vice President for

Administration and Business Affairs

The University of Texas

Health Science Center at San Antonio

San Antonio, Texas 78284-7862 

	5.6
	Upon
receiving a first notice of allowance for a patent application covered under Paragraph 2.7 (Patent Rights), Licensee must reimburse Board for all its
out-of-pocket expenses thus far incurred in filing, prosecuting, enforcing and maintaining exclusively licensed Patent Rights, up to a maximum reimbursement of $10,000 during
the Term. Notwithstanding the $10,000 maximum reimbursement during the Term, if the Term is extended pursuant to Paragraph 6.1, Licensee 

4

 

agrees
to reimburse Board for all its Patent Costs incurred prior to the effective date of the extension, up to a maximum reimbursement of $15,000. 

	6.
	TERM
AND TERMINATION

	6.1
	The
term of this Agreement is from the Effective Date until the third anniversary thereof ("Term"). The Term may be extended for additional periods of 2 years by mutual
agreement of the Parties. However, the Term shall not exceed the term or terms of any patents covered by Patent Rights.

	6.2
	Any
time after 1 year from the Effective Date, Board and University have the right to terminate the exclusivity of this license in any national political jurisdiction in the
Licensed Territory if Licensee, within 90 days after receiving written notice from University of intended termination of exclusivity, fails to provide written evidence reasonably satisfactory
to University that Licensee or its sublicensee has commercialized or is actively attempting to commercialize a licensed invention in such jurisdiction(s).

	6.3
	Any
time after 2 years from the Effective Date, Board and University have the right to terminate this license in any national political jurisdiction in the Licensed Territory
if Licensee, within 90 days after receiving written notice from University of intended termination, fails to provide written evidence reasonably satisfactory to University that Licensee or its
sublicensee has commercialized or is actively attempting to commercialize a licensed invention in such jurisdiction(s).

	6.4
	The
following definitions apply to Article 6: (i) "Commercialize" means having Sales of Licensed Products in such jurisdiction; and (ii) "Active attempts to
commercialize" means having Sales of Licensed Products or an effective, ongoing and active research, development, manufacturing, marketing or sales program as commercially appropriate, directed toward
obtaining regulatory approval, production or Sales of Licensed Products in any jurisdiction, and plans acceptable to University, in its sole discretion, to commercialize licensed inventions in the
jurisdiction(s) that University intends to terminate.

	6.5.
	Licensee
agrees to develop a vigorous sublicensing program to effect commercialization of Licensed Subject Matter in any portion of the Licensed Field that Licensee does not exploit.

	6.6.
	This
Agreement will earlier terminate:

	a.
	automatically
if Licensee becomes bankrupt or insolvent and/or if the business of Licensee is placed in the hands of a receiver, assignee, or trustee, whether by voluntary act of
Licensee or otherwise; or

	b.
	upon
30 days written notice from Board if Licensee breaches or defaults on its obligation to make payments (if any are due) or reports, in accordance with the terms of
Article 5, unless, before the end of the 30 day period, Licensee has cured the default or breach and so notifies Board, stating the manner of the cure; or

	c.
	upon
90 days written notice if Licensee breaches or defaults on any other obligation under this Agreement, unless, before the end of the 90 day period, Licensee has cured
the default or breach or is acting diligently to make such cure, and so notifies Board, stating the manner of the cure; or

	d.
	at
any time by mutual written agreement between Licensee, University, and Board, upon 180 days written notice to all parties listed in Paragraph 15.2 and subject to any
terms herein which survive termination; or

	e.
	under
the provisions of Paragraphs 6.2 and 6.3 if invoked. 

5

 

	6.7.
	If
this Agreement is terminated for any cause:

	a.
	nothing
herein will be construed to release either Party of any obligation matured prior to the effective date of the termination;

	b.
	after
the effective date of the termination, Licensee may sell all Licensed Products and parts therefor it has on hand at the date of termination, if it pays earned royalties thereon
according to the terms of Article 5; and

	c.
	Licensee
will be bound by the provisions of Articles 10 (Indemnification), 11 (Use of Board and Component's Name), and 12 (Confidential Information) of this Agreement.

	7.
	INFRINGEMENT
BY THIRD PARTIES

	7.1
	Licensee,
at its expense, must enforce any patent exclusively licensed hereunder against infringement by third parties and it is entitled to retain recovery from such enforcement.
Licensee must pay Board a royalty on any monetary recovery if the monetary recovery is for damages or a reasonable royalty in lieu thereof. If Licensee does not file suit against a substantial
infringer of a patent within 6 months of knowledge thereof, then Board may enforce any patent licensed hereunder on behalf of itself and Licensee, Board retaining all recoveries from such
enforcement and/or reducing the license granted hereunder to non-exclusive.

	7.2
	In
any infringement suit or dispute, the Parties agree to cooperate fully with each other. At the request and expense of the Party bringing suit, the other Party will permit access to
all relevant personnel, records, papers, information, samples, specimens, etc., during regular business hours.

	8.
	ASSIGNMENT 

Except
in connection with the sale of substantially all of Licensee's assets to a third party, this Agreement may not be assigned by Licensee without the prior written consent of Board, which will not
be unreasonably withheld. 

	9.
	PATENT
MARKING 

Licensee
must permanently and legibly mark all products and documentation manufactured or sold by it under this Agreement with a patent notice as may be permitted or required under Title 35, United
States Code. 

	10.
	INDEMNIFICATION 

Subject
to the terms of this Agreement, Licensee agrees to hold harmless and indemnify Board, System, University, its Regents, officers, employees and agents from and against any claims, demands, or
causes of action whatsoever, including without limitation those arising on account of any injury or death of persons or damage to property caused by, or arising out of, or resulting from, the exercise
or practice of the license granted hereunder by Licensee, its Affiliates, or their officers, employees, agents, or representatives, except for liabilities resulting from the indemnified parties' gross
negligence or willful acts or omissions. 

Subject
to the terms of this Agreement, the Board and System agree, to the extent authorized under the Constitution and laws of the State of Texas, to hold harmless and indemnify Licensee, its
officers, employees and agents from liability resulting from the negligent acts or omissions of Board, System, University, its Regents, officers, employees and agents pertaining to the activities to
be carried out pursuant to the obligations of this Agreement, except for liabilities resulting from the indemnified parties' negligence or willful acts or omissions. 

	11.
	USE
OF BOARD AND COMPONENT'S NAME 

Licensee
may not use the name of University, System, or Board without express written consent. 

6

 
	12.
	CONFIDENTIAL
INFORMATION AND PUBLICATION

	12.1
	Board
and Licensee each agree that all information contained in documents marked "confidential" and forwarded to one by the other are to (i) be received in strict confidence,
(ii) be used only for the purposes of this Agreement, and (iii) not be disclosed by the recipient Party, its agents or employees without the prior written consent of the other Party,
except to the extent that the recipient Party can establish competent written proof that such information:

	(a.)
	was
in the public domain at the time of disclosure;

	(b.)
	later
became part of the public domain through no act or omission of the recipient Party, its employees, agents, successors or assigns;

	(c.)
	was
lawfully disclosed to the recipient Party by a third party having the right to disclose it;

	(d.)
	was
already known by the recipient Party at the time of disclosure;

	(e.)
	was
independently developed by the recipient Party; or

	(f.)
	is
required by law or regulation to be disclosed.

	12.2
	Each
Party's obligation of confidence hereunder shall be fulfilled by using at least the same degree of care with the other Party's confidential information as it uses to protect its
own confidential information. This obligation shall exist while this Agreement is in force and for a period of 3 years thereafter.

	12.3
	University
will submit its manuscript for any proposed publication of research related to Licensed Subject Matter to Licensee at least 30 days before publication, and Licensee
shall have the right to review and comment upon the publication in order to protect Licensee's confidential information. Upon Licensee's request, publication will be delayed up to 60 additional days
to enable Licensee to secure adequate intellectual property protection of Licensee's property that would be affected by the publication.

	13.
	PATENTS
AND INVENTIONS

	13.1
	If
after consultation with Licensee, both Parties agree that a patent application should be filed for Licensed Subject Matter, Board will prepare and, after consultation with
Licensee, file the appropriate patent applications, and Licensee will pay the reasonable cost of searching, preparing, filing, prosecuting, and maintaining same. If Licensee notifies Board that it
does not intend to pay the cost of an application, or if Licensee does not respond or make an effort to agree with Board on the disposition of rights in the subject invention, then Board may file an
application at its own expense and Licensee will have no rights to the invention. Board will provide Licensee a copy of any patent application for which Licensee has paid the cost of filing, as well
as copies of any documents received or filed with the respective patent office during the prosecution thereof.

	14.
	ALTERNATE
DISPUTE RESOLUTION

	14.1
	The
Parties agree that any dispute or controversy arising out of or relating to this Agreement, its construction, or its actual or alleged breach will be decided by mediation, in
accordance with the provisions of TEX. CIV. PRAC. & REM. Codess.ss.154.001- 154.073 (Vernon 1997) and TEX. GOV'T Codess.ss.2008.001- 2008.055 (Vernon 1997 & Supp.
1998). If the mediation does not result in a resolution of such dispute or controversy, it will be decided by another method of alternate dispute resolution in accordance with the provisions of TEX.
CIV. PRAC. & REM. Codess.ss.154.001- 154.073 (Vernon 1997) and TEX. GOV'T Codess.ss.2008.001- 2008.055 (Vernon 1997 & Supp. 1998), including without limitation,
arbitration, conducted in the city of San Antonio, Texas in accordance with the License Agreement Arbitration Rules of the American Arbitration Association. The arbitration panel will include members
knowledgeable in the commercialization 

7

 

and
licensing of medical devices, and intellectual property law. The decision of the arbitration must be sanctioned by a court of law having jurisdiction to be binding upon and enforceable by the
Parties. Judgment upon the award rendered may be entered in the highest court or forum having jurisdiction, state or federal. The provisions of this Article 14 will not apply to decisions on
the validity or enforceability of patent claims or to any dispute or controversy as to which any treaty or law prohibits such arbitration. 

	15.
	GENERAL

	15.1
	This
Agreement constitutes the entire and only agreement between the Parties for Licensed Subject Matter and all other prior negotiations, representations, agreements, and
understandings are superseded hereby. No agreements altering or supplementing the terms hereof may be made except by a written document signed by both Parties.

	15.2
	Any
notice required by this Agreement must be given by prepaid, first class, certified mail, return receipt requested, addressed in the case of Board to: 

Board
of Regents

The University of Texas System

201 West 7th Street

Austin, Texas 78701

ATTENTION: Office of General Counsel

FAX: (512) 499-4523

PHONE: (512) 499-4462 

with
copies to: 

The
University of Texas Health Science Center at San Antonio

7703 Floyd Curl Drive

San Antonio, Texas 78284-7862

ATTENTION: Jack C. Park, Esq.

Executive Director of Legal Affairs and Technology Licensing

FAX: (210) 567-2047

PHONE: (210) 567-2020 

or
in the case of Licensee to:
 NOMOS CORPORATION

2591 Wexford Bayne Road

Sewickley, PA 15143 

ATTENTION:
Anil Rastogi, President and CEO

FAX: (724) 934-5488

PHONE: (724) 934-8200 

or
other addresses as may be given from time to time under the terms of this notice provision. 

	15.3
	Licensee
must comply with all applicable federal, state and local laws and regulations in connection with its activities pursuant to this Agreement.

	15.4
	This
Agreement will be construed and enforced in accordance with the laws of the United States of America and of the State of Texas.

	15.5
	Failure
of Board to enforce a right under this Agreement will not act as a waiver of that right or the ability to later assert that right relative to the particular situation
involved.

	15.6
	Headings
are included herein for convenience only and shall not be used to construe this Agreement. 

8

 
	15.7
	If
any part of this Agreement is for any reason found to be unenforceable, all other parts nevertheless remain enforceable. 

IN
WITNESS WHEREOF, the Parties hereto have caused their duly authorized representatives to execute this Agreement. 

	
BOARD OF REGENTS OF THE NOMOS CORPORATION

UNIVERSITY OF TEXAS SYSTEM
	

By	
 	

/s/ JOHN P. HOWE	
 	

By	
 	

/s/ ANIL RASTOGI
	 	 	
 John P. Howe, III, M.D.
 President
 University of Texas

Health Science Center at San Antonio	 	 	 	
 Anil Rastogi
 President and CEO
	

Approved as to Form:	
 	

 	
 	

 
	

By	
 	

/s/ BETHLYNN MAXWELL    21 Oct. '98	
 	

 	
 	

 
	 	 	
 BethLynn Maxwell
 Office of General Counsel	 	 	 	 
	

Approved as to Content:	
 	

 	
 	

 
	

By	
 	

/s/ R.B. PRICE	
 	

 	
 	

 
	 	 	
 R.B. Price
 Executive Vice President for

Administration and Business Affairs	 	 	 	 

9

QuickLinks

Exhibit 10.21

PATENT LICENSE AGREEMENT

EXECUTION COPY RECITALS

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00060-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00060-of-00352.parquet"}]]